Volume 16, Number 9—September 2010
Dispatch
Human Herpesvirus 8 Genotype E in Patients with Kaposi Sarcoma, Peru
Table A1
Patient and tumor characteristics and results of immunohistochemical analyses and molecular typing of VR1 and VR2 of the open reading frame K1 of HHV-8 in patients with KS, Peru*
| ID IP | Age, y/sex | Origin | Lesion | No. lesions | Biopsy site | HIV status | Clinical diagnosis | Level of spindle cells infiltration | Perls | CD 34 | LANA-1 | VR1 PCR† |
VR2 PCR |
Subtype by molecular analysis | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VR1 outer | VR1 inner | VR2 outer | VR2 inner | ||||||||||||||
| 04/0480 | 51/M | Mestizo | Nodule | 1 | Neck | + | AIDS KS | ++ | +++ | ++ | ++ | + E | + E | – | + E | E | |
| 04/0484 | 29/M | Mestizo | Nodule | Multiple | Nose | + | AIDS KS | +++ | ++ | ++ | ++ | + C | + C | – | – | C | |
| 04/0485 | 29/M | Mestizo | Nodule | Multiple | Head | + | AIDS KS | +++ | + | ++ | ++ | + C | + C | – | + C | C | |
| 04/0489 | 32/M | Mestizo | Macula | 1 | Hard palate | + | AIDS KS | ++ | ++ | ++ | + | – | + B | – | + B | B | |
| 04/0492 | 34/F | Mestizo | Macula | Multiple | Face | + | AIDS KS | +++ | +++ | ++ | ++ | + A | + A | – | + A | A | |
| 04/0497 | 32/M | Mestizo | Patch | Multiple | Chest | + | AIDS KS | +++ | +++ | ++ | ++ | – | + C | – | +‡ | C | |
| 06/0749 | 35/F | Mestizo | Macula | Multiple | Hard palate | + | AIDS KS | + | + | + | + | + C | + C | – | – | C | |
| 06/0750 | 35/M | Mestizo | Macula, nodule | Multiple | Hard palate | + | AIDS KS | ++ | ++ | + | ++ | – | +‡ C | – | – | C | |
| 06/0758 | 37/M | Mestizo | Nodule | 1 | Eyelid | + | AIDS KS | + | ++ | ++ | +/− | – | + A | – | – | A | |
| 06/0772 | 24/M | Mestizo | Papula, nodule | Multiple | Upper limb | + | AIDS KS | + | + | + | + | + E | + E | + E | + E | E | |
| 04/0479 | 83/F | Mestizo | Papula | 1 | Lower limb | – | Classic KS | +++ | + | + | ++ | – | + C | – | + C | C | |
| 04/0482 | 75/M | Mestizo | Nodule | Multiple | Hand | – | Classic KS | +++ | +++ | ++ | ++ | +‡ | + C | – | + C | C | |
| 04/0487 | 70/F | Quechua | Nodule | 1 | Foot | – | Classic KS | +++ | +++ | + | ++ | – | + C | – | + C | C | |
| 04/0488 | 75/M | Mestizo | Nodule | Multiple | Foot | – | Classic KS | +++ | ++ | + | ++ | – | + C | – | + C | C | |
| 04/0498 | 75/M | Quechua | Nodule | 1 | Foot | – | Classic KS | +++ | +++ | ++ | ++ | + A | + A | + A | + A | A | |
| 06/0733 | 58/M | Mestizo | Macula | Multiple | Hard palate | – | Classic KS | – | - | + | +/− | – | + C | – | – | C | |
| 06/0739 | 46/M | Mestizo | Patch | Multiple | Upper limb | – | Classic KS | + | +/− | ++ | ++ | – | + A | – | + A | A | |
| 06/0741 | 30/M | Mestizo | Nodule | 1 | Face | – | Classic KS | +++ | + | ++ | +++ | + A | + A | + A | +‡ | A | |
| 06/0743 | 30/M | Mestizo | Nodule | Multiple | Face | – | Classic KS | ++ | ++ | + | ++ | + C | + C | – | – | C | |
| 06/0745 | 31/M | Mestizo | Papula, nodule | Multiple | Lower limb | – | Classic KS | + | + | + | + | – | + C | – | – | C | |
| 06/0751 | 26/M | Quechua | Macula | 1 | Hard palate | – | Classic KS | +++ | +++ | + | ++ | + C | + C | – | +‡ | C | |
| 06/0754 | 63/F | Mestizo | Nodule | Multiple | Neck | – | Classic KS | ++ | +/− | +++ | +++ | + A | + A | – | +‡ | A | |
| 06/0767 | 76/F | Quechua | Nodule | 1 | Lower limb | – | Classic KS | – | – | +++ | – | – | + C | + C | + C | C | |
| 04/0491 | 63/F | Mestizo | Nodule | ND | Foot | – | ND | ++ | + | + | ++ | – | +‡ A | – | +‡ A | A | |
| 04/0494 | 75/F | ND | Nodule | ND | Foot | – | ND | ++ | ++ | + | ++ | + A | + A | – | – | A | |
*KS, Kaposi sarcoma; VR1 and VR2, variable region 1 or 2 of the open reading frame K1 of HHV-8; HHV-8, human herpesvirus 8; ID IP, identification of the specimen given by the Institut Pasteur pathologic unit; LANA, latency-associated nuclear antigen; AIDS KS, KS occurring with HIV-1 infection; –, no amplification product. ND, not determined.
†For VR1, the first PCR was performed with the primer set VR1S (ATCCTTGCCAAYATCCTGGTATTGBAA) / VR1AS1 (ACGATTTGACAGGCGAGACGACAGC) (amplification of 373 bp) and followed by a nested PCR with a second set of primers VR1S/VR1AS2 (ACAATRCAAAGTAACABGCTGRCC) for the amplification of a 220-bp fragment. For VR2 amplification, the first PCR was performed by using the primer set VR2S (TCTCGCCTGTCAAATCBTMTATGT) / VR2AS1(AGTACCAMTCCACTGGTTGYGTAT) amplification of 314 bp and followed by a nested PCR with a second set of primers VR2S/VR2AS2 (AGTTCCTAMGATACCAMACATGGTT) for the amplification of a 240–300-bp fragment. Amplified PCR products of the appropriate size were then purified from gel, cloned, sequenced as previously described (14). Sequences were verified on both DNA strands.
‡Weak PCR signal.
1These authors contributed equally to this article.
